PBAC's latest decision on Cabotegravir and rilpivirine: Recommended with restriction (2021). Considered for Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) and have no known or suspected resistance to either cabotegravir or rilpivirine.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
2
first 2021
Submissions
2
2021 → 2021
Eligible population
Adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA <50 copies/mL) and switching therapy, with no known or suspected resistance to cabotegravir or rilpivirine
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48